User profiles for S Ozaki

Shogo Ozaki

Kyushu University
Verified email at phar.kyushu-u.ac.jp
Cited by 1658

Regulation of the replication cycle: conserved and diverse regulatory systems for DnaA and oriC

T Katayama, S Ozaki, K Keyamura… - Nature Reviews …, 2010 - nature.com
… In S phase of the cell cycle in Drosophila melanogaster , Cul4–Cdt2–clamp complexes
promote degradation of E2F, a key transcription factor that activates important genes for S phase …

ANCA-associated vasculitis: diagnostic therapeutic strategy

S Ozaki - Allergology International, 2007 - Elsevier
… Thus, etanercept was ineffective for the maintenance of disease remission in Wegener’s
granulomatosis, and considering its increased risk of malignancy, should not be used for the …

Sleep and mood disorders

RM Benca, M Okawa, M Uchiyama, S Ozaki… - Sleep medicine …, 1997 - Elsevier
… After TSD, the subsequent recovery sleep was scheduled 6 hours earlier than patient’s
conventional retiring and waking times. The advanced sleep schedule was gradually delayed 1 …

Expression of the Fas ligand in cells of T cell lineage.

…, N Arai, S Ozaki, K Nakao, S Nagata - … (Baltimore, Md.: 1950 …, 1995 - journals.aai.org
… In this regard, it should be noted that the mRNAs of the small intestine were prepared from
the whole tissues including Peyer’s patches containing lymphoid cells. Because of the T-…

Clearance of circulating endothelin-1 by ETB receptors in rats

T Fukuroda, T Fujikawa, S Ozaki, K Ishikawa… - Biochemical and …, 1994 - Elsevier
Exogenous endothelin (ET) is rapidly cleared from the circulation. We investigated which ET
receptor subtypes (ET A and ET B ) participate in ET-1 clearance. Following an intravenous (…

Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788.

…, T Fukuroda, T Fukami, S Ozaki… - Proceedings of the …, 1994 - National Acad Sciences
We describe the characteristics of a potent and selective endothelin (ET) B-receptor
antagonist, BQ-788 [N-cis-2,6-dimethylpiperidinocarbonyl-L-gamma-methylleucyl-D -1- …

Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma

…, T Hashimoto, S Ozaki, S Wakatsuki… - Blood, The Journal …, 2002 - ashpublications.org
Multiple myeloma (MM) cells cause devastating bone destruction by activating osteoclasts in
the bone marrow milieu. However, the mechanism of enhanced bone resorption in patients …

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion

…, T Hashimoto, S Kido, T Oshima, H Shibata, S Ozaki… - Blood, 2004 - ashpublications.org
Multiple myeloma (MM) expands in the bone marrow and causes devastating bone destruction
by enhancing osteoclastic bone resorption in its vicinity, suggesting a close interaction …

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

…, JH Lee, C Shustik, D Waller, WJ Chng, S Ozaki… - Leukemia, 2017 - nature.com
Introduction of new myeloma therapies offers new options for patients refractory to
immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs). In this multicenter study, patients …

Runx3 controls the axonal projection of proprioceptive dorsal root ganglion neurons

K Inoue, S Ozaki, T Shiga, K Ito, T Masuda… - Nature …, 2002 - nature.com
Dorsal root ganglion (DRG) neurons specifically project axons to central and peripheral
targets according to their sensory modality. The Runt-related genes Runx1 and Runx3 are …